Original Article

DEXAMETHASONE STRESS TEST:
A PILOT CLINICAL STUDY FOR IDENTIFICATION OF
INDIVIDUALS HIGHLY PRONE TO DEVELOP TYPE 2 DIABETES

Nader Taheri, MD[1]; Ashraf Aminorroaya, MD[1];
Faramarz Ismail-Beigi, MD, PhD[2]*; Massoud Amini, MD[1]*

ABSTRACT

Objective: We examined whether the "Dexamethasone Stress Test" exhibits the requisite high predictive ability to identify individuals highly prone to develop type 2 diabetes mellitus (T2DM).

Methods: Seven years ago, we administered an oral glucose tolerance test (OGTT) to 33 individuals without T2DM and repeated the OGTT 24 hours after a single oral dose of 8 mg dexamethasone (Dex); all participants had a first-degree relative with T2DM, and close to half had prediabetes. We calculated receiver operating characteristic (ROC) curves for all parameters derived from the OGTT before and after Dex in individuals who subsequently developed diabetes compared to individuals who did not.

Results: At 7 years of follow-up, 9 individuals had developed T2DM, while 24 remained without diabetes. None of the OGTT-derived parameters before administration of Dex had an area under the ROC curve of >0.8. However, 24 hours after Dex, three parameters, including fasting plasma insulin, homeostatic model assessment–insulin resistance, and 2-hour plasma glucose level, exhibited areas under the ROC curves of 0.84, 0.86, and 0.92, respectively.

Conclusion: The Dexamethasone Stress Test appears to be a good to excellent test in identifying individuals highly prone to develop T2DM. (**Endocr Pract. 2018;24: 894-899**)

Abbreviations:
AUC = area under the curve; **Dex** = dexamethasone; **HOMA-IR** = homeostatic model assessment–insulin resistance; **NGT** = normal glucose tolerance; **OGTT** = oral glucose tolerance test; **PreDiab** = prediabetes; **ROC** = receiver operating characteristic; **T2DM** = type 2 diabetes mellitus

INTRODUCTION

The pandemic of type 2 diabetes mellitus (T2DM) affects millions of people worldwide, with the developing world having the highest incidence (1-3). The rising incidence and prevalence of T2DM is in large part due to increased dietary caloric intake and decreased physical activity (4,5). Several patient characteristics—or risk factors—lead to greater predisposition to developing T2DM; these include having prediabetes (PreDiab), having a first-degree relative with T2DM, being obese or a smoker, or having hypertension or dyslipidemia (6-8). However, none of these factors either singly or in combination have exhibited the requisite high predictor value in identifying a very-large fraction of people that are highly prone to develop the disease (6,8). For example, most overweight or obese people, and many individuals with PreDiab, do not develop T2DM over the subsequent years (4,5). Nevertheless, identification of people at very-high risk to develop T2DM is of great importance in guiding our efforts and utilizing our resources that are needed for prevention of the disease.

We designed a study 7 years ago to explore the predictive value of the "Dexamethasone Stress Test." We based the idea of using dexamethasone (Dex) on the well-known stimulatory effect of glucocorticoids to increase hepatic glucose production and to increase insulin resistance in peripheral tissues, including the liver (9-11). In fact, several previous studies had raised the possibility that the response to exposure to glucocorticoids could potentially be used to identify persons prone to developing T2DM (12-19). What we added to the above studies and to our proposed test was to challenge with a glucose load added to an acute exposure to Dex.

The current analysis is the outcome of the study that was initiated 7 years ago to examine the effect of Dex on glucose homeostasis; all enrolled individuals had a first-degree relative with T2DM (20). Following an oral glucose tolerance test (OGTT) to exclude T2DM, 43 individuals received an 8-mg oral dose of Dex, followed by an OGTT the next morning (20).

We used an 8-mg dose of Dex for the "Dex Stress Test" based on our earlier observations using repeated OGTTs in a group of healthy adult males and females with no family history of T2DM testing the effect of a single dose of 2, 4, or 8 mg Dex on glucose homeostasis (21). We found that, when compared to the OGTT before Dex, the 8-mg dose of Dex resulted in the greatest increment in insulin secretion and insulin resistance. Furthermore, the high excursions in glucose and insulin levels observed during the OGTT performed at 24 hours after Dex were largely dissipated at 48 hours (21). Based on the above, we reasoned that the glucose load given for the OGTT combined with the effects of Dex on glucose homeostasis could potentially identify at-risk individuals with a high predictive value.

We performed an OGTT (7 years ago) in 43 individuals with normal glucose tolerance (NGT) or with PreDiab before and 24 hours after receiving the 8-mg dose of Dex (20). The present analysis is the outcome of the above study with the aim of assessing whether the Dex Stress Test has the requisite predicative ability to identify individuals that will develop T2DM. Of 43 persons in the original NGT plus PreDiab groups who received Dex (20 persons in the PreDiab group and 23 persons in the NGT group), we have follow-up data on 33 individuals at 7 years of follow-up; the group is comprised of 24 persons who have remained without diabetes and 9 individuals who developed T2DM. Here, we examine whether any of the parameters derived from the OGTTs performed either before or 24 hours after the 8-mg dose of Dex in the 9 individuals who developed T2DM differed from values in the 24 participants who also received Dex but did not develop diabetes.

METHODS

The study was initiated at (and funded by) the Isfahan Endocrine and Metabolism Research Center (IEMRC) at the Isfahan University of Medical Sciences (IUMS), Iran, between October 2009 and May 2010. The Ethics Committee of IUMS approved the study design and consent process in accordance with the Declaration of Helsinki. The full study protocol is available at the IEMRC.

Baseline data of the original study group performed 7 years ago was reported previously (20). Forty-three individuals had an OGTT, received 8 mg of Dex, and had a repeat OGTT 24 hours after Dex. In the subsequent 7 years of follow-up, 5 persons each from the PreDiab and NGT groups were lost to follow-up. The current analysis is based on 33 individuals in whom we have follow-up data. Diagnosis of T2DM at 7 years of follow-up was based on a repeat OGTT performed on all 33 participants according to the American Diabetes Association criteria (22). Calculation of the parameters derived from the OGTTs was described previously (20,21). Here, we compare parameters of glucose homeostasis derived from before and after receiving Dex 7 years ago in those who did and did not develop T2DM. Receiver operating characteristic (ROC) curves were calculated for all the metabolic parameters derived from the OGTT performed prior to receiving Dex and at 24 hours after Dex. We used the trapezoid method to calculate the area under the curve (AUC) of each ROC curve. We considered parameters with AUCs exceeding 0.80 to have a good to excellent predictive value (23) in identifying persons highly prone to develop T2DM. Unless specified, data are shown as mean ± standard error (SE), and the Student's *t* test was used, with *P*<.05 considered significant.

RESULTS

At 7 years of follow-up, data on 33 individuals (15 persons from the PreDiab and 18 from the NGT group) of the original 43 persons who had received Dex were available; 10 individuals were lost to follow-up. Nine individuals developed T2DM at follow-up; 7 patients were from the original PreDiab group, and 2 were from the NGT group.

Baseline characteristics of the 33 individuals who received Dex are summarized in Table 1. The predominance of females in large part reflects the unequal distribution in the original study (20). Individuals who developed diabetes were younger, had higher body weight, body mass index, waist circumference, and systolic and diastolic blood pressure; however, only the difference in body weight was highly statistically significant between the two groups.

Table 2 summarizes glucose and insulin levels measured during the OGTT performed 7 years ago in individuals currently without and those with diabetes; values are shown from both before Dex and 24 hours after the 8-mg dose of Dex. Also shown (in the far right column) is the statistical significance of changes in glucose and insulin levels 24 hours after Dex in individuals who did not develop versus those who did develop T2DM. In both

groups, all blood glucose and insulin levels were higher at all time points of the OGTT after Dex. In addition, at all time points, all values after Dex were higher in those who developed T2DM compared to those who did not. However, after Dex, only fasting glucose, 2-hour glucose, and fasting insulin levels were significantly different between the two groups.

Table 3 shows parameters of insulin sensitivity and insulin resistance calculated from the results listed in Table 2 using equations detailed previously (20). Of note, homeostatic model assessment–insulin resistance (HOMA-IR), HOMA–beta-cell function (HOMA-B), AUC of insulin, and AUC of glucose were higher and the Matsuda Index

lower in both groups following Dex. Similar to Table 2, the column on the far right shows the statistical significance between parameters in individuals after Dex who did not and who did develop T2DM. Of note, highly significant differences after Dex between the two groups included increases in HOMA-IR and AUC for glucose and a decrease in Matsuda Index consistent with greater insulin resistance in response to Dex in those who subsequently developed diabetes.

We determined the AUC of ROC curves for all values measured at baseline before Dex and 24 hours after Dex to evaluate their predictive strength in identifying individuals at high risk for developing T2DM (Table 4). A ROC curve AUC >0.8 is considered to have a good to excellent predictive value (23). AUCs measured before Dex ranged from 0.53 to 0.78. After Dex, there was no systematic trend for the AUCs to increase or decrease, although many increased. However, the AUC of three parameters increased and became >0.80, including ROC curve AUCs for fasting insulin (0.84), HOMA-IR (0.86), and 2-hour glucose (0.92). Figure 1 shows the sensitivity and specificity of these three parameters using two different "cutpoints" for each ROC graph.

DISCUSSION

Identification of individuals prone to develop T2DM with requisite high predictive ability has been difficult (6-8,24). The results of this study show that the homeostasis parameters derived from the OGTT performed before Dex all had ROC curve AUCs ≤0.78 (range, 0.53 to 0.78), with some having AUCs between 0.70 and 0.78, signify-

Table 1
Characteristics of Individuals at Baseline Who Did Not and Those Who Did Develop Type 2 Diabetes During Follow-Up

Characteristic	No diabetes[a] (n = 24)	Diabetes[a] (n = 9)	P value
Male/female	1/23	1/8	--
Age (years)	46.7 ± 6.4	43.3 ± 7.3	.20
Height (cm)	156.8 ± 6.0	159.4 ± 5.8	.27
Weight (kg)	71.1 ± 8.5	98.0 ± 1.4	.003
BMI (kg/m²)	29.6 ± 5.6	31.3 ± 5.6	.45
Waist (cm)	93.2 ± 12.5	105.1 ± 22.1	.06
Systolic BP (mm Hg)	117.0 ± 10.7	125.0 ± 7.0	.05
Diastolic BP (mm Hg)	78.3 ± 8.4	84.4 ± 4.6	.05

Abbreviations: BMI = body mass index; BP = blood pressure.
[a]Mean ± SD

Table 2
Derived Values From OGTTs Performed at Baseline Before and After Receiving 8 mg Dexamethasone in Individuals Who Did and Those Who Did Not Develop Type 2 Diabetes at 7 Years of Follow-Up

Derived values	No diabetes (n = 24)			Diabetes (n = 9)			P value after Dex[c]
	Before Dex[a]	After Dex[a]	P value[b]	Before Dex[a]	After Dex[a]	P value[b]	
Fasting glucose (mg/dL)	94.9 ± 1.7	107.7 ± 3.4	.01	102.4 ± 2.8	120.7 ± 5.4	.002	.05
Glucose 30 min (mg/dL)	133.1 ± 4.8	163.9 ± 8	.01	152.8 ± 0.9	180.3 ± 7.5	.002	.3
Glucose 60 min (mg/dL)	138.9 ± 6.2	190.5 ± 11.1	.01	186.3 ± 13.8	216 ± 13.5	.03	.2
Glucose 120 min (mg/dL)	121 ± 4.9	158.1 ± 7.6	.01	146 ± 8.6	216.6 ± 19.4	.002	.002
Fasting insulin (µIU/mL)	6.5 ± 0.53	12.7 ± 8.5	.01	9 ± 1	19.9 ± 3.3[d]	.005	.002
Insulin 30 min (µIU/mL)	42.8 ± 5.3	71.8 ± 8.5	.01	55.4 ± 11.9	84.9 ± 18.4	.07	.5
Insulin 60 min (µIU/mL)	53.1 ± 6.5	100.9 ± 11.6	.01	81 ± 13.9	111.7 ± 21.1	.04	.7
Insulin 120 min (µIU/mL)	44.9 ± 5.5	89.4 ± 14.2	.01	73.9 ± 13.7	127.3 ± 36.5	.08	.26

Abbreviation: Dex = dexamethasone; OGTT = oral glucose tolerance test.
[a]Values are means ± SE.
[b]P values reflect the difference before and after Dex in each group.
[c]P values reflect the difference after Dex between the two groups.
[d]Denotes that n = 8 for this measure.

Table 3
Derived Values From the Results of OGTTs Shown in Table 2 in Participants
Who Did and Those Who Did Not Develop Diabetes at 7 Years of Follow-Up

Derived values	No diabetes (n = 24)			Diabetes (n = 9)			P value after Dex[d]
	Before Dex[a]	After Dex[a]	P value[c]	Before Dex[a]	After Dex[a,b]	P value[c]	
HOMA-IR	1.5 ± 0.13	3.4 ± 0.35	.01	2.3 ± 0.26	6.1 ± 1.1	.007	.002
HOMA-B	76.9 ± 6.7	115.6 ± 13.1	.01	86.2 ± 14.6	125 ± 20.4	.004	.40
Matsuda Index	13.5 ± 0.53	7.2 ± 0.35	.01	10.9 ± 0.77	5.4 ± 0.5	.001	.006
Insulinogenic Index	0.97 ± 0.12	1.1 ± 0.18	.18	0.85 ± 0.24	1 ± 0.34	.30	.70
Disposition Index1	13.2 ± 1.8	8.2 ± 1.29	.03	8.5 ± 2	6 ± 2	.12	.30
Disposition Index2	81.7 ± 3.2	84.5 ± 3.1	.40	92.8 ± 5.9	98.9 ± 7.7	.22	.01
AUC-Glucose	850 ± 28	1,103 ± 47	.01	1,049 ± 58	1,302 ± 69	.001	.03
AUC-Insulin	5,123 ± 542	9,569 ± 1023	.01	6,614 ± 874	10,055 ± 1,607	.03	.32

Abbreviations: AUC = area under the curve; Dex = dexamethasone; HOMA-B = homeostatic model assessment–beta-cell function; HOMA-IR = homeostatic model assessment–insulin resistance; OGTT = oral glucose tolerance test.
[a]Values are mean ± SE.
[b]n = 8, except for AUC-Glucose, where n = 9.
[c]P values reflect the difference before and after Dex in each group.
[d]P values reflect the difference after Dex between the two groups.

Table 4
AUC of ROC Curves Calculated Before
Dex and 24 Hours After Dex in Individuals Who
Developed T2DM Compared to Those Who Did Not

AUC of ROC curves		
Parameters	Before Dex	After Dex
Fasting Glucose	0.63	0.76
Glucose, 30 min	0.68	0.76
Glucose, 60 min	0.78	0.62
Glucose, 120 min	0.68	0.92
Fasting Insulin	0.65	0.84
Insulin, 30 min	0.60	0.58
Insulin, 60 min	0.72	0.60
Insulin, 120 min	0.64	0.61
HOMA-IR	0.76	0.86
HOMA-B	0.54	0.60
Matsuda Index	0.55	0.77
Insulinogenic Index	0.53	0.52
Disposition Index1	0.62	0.55
Disposition Index2	0.60	0.78
AUC Glucose	0.78	0.78
AUC Insulin	0.71	0.65

Abbreviations: AUC = area under the curve; Dex = dexamethasone; HOMA-B = homeostatic model assessment–beta-cell function; HOMA-IR = homeostatic model assessment–insulin resistance; ROC = receiver operating characteristic; T2DM = type 2 diabetes mellitus.

ing modest to moderate predictive value. However, three parameters measured 24 hours after an 8-mg dose of Dex appear to be good to excellent predictors of development of T2DM in subsequent years. The known increase in insulin resistance after Dex (9-11) added to the glucose load of the OGTT appears to bring about the largest change in many parameters of glucose homeostasis. The most predictive parameters with AUCs of >0.80 after Dex were fasting insulin, HOMA-IR, and 2-hour glucose level during the OGTT. It is worth noting that two of these three parameters (fasting insulin level and HOMA-IR) require only a fasting blood sample and hence lend themselves to a less complex and perhaps a more useful and practical screening test.

Our results are in general agreement with previous studies. Durck et al (25) performed OGTTs on normoglycemic individuals with a first-degree relative with T2DM before and after treatment with 2 mg of Dex twice a day for 4 days. They noted that fasting and 2-hour glucose values and HOMA-IR measured at baseline were the best predictors of dysglycemia at 10 years; of note, 4 individuals from the original group of 20 had developed diabetes during the 10 years. Other investigators have reported that sensitivity of beta cells to glucose and whole-body insulin sensitivity (26) and first-phase insulin release in response to glucose (27) are good markers of future development of T2DM over the course of 5 and 25 years, respectively. Finally, Hanley et al (28) reported that beta-cell function and whole-body insulin resistance derived from intravenous glucose tolerance tests were good predictors of T2DM over a 5-year period, and Ferrannini et al (29), using OGTT, found fasting and 2-hour glucose were independent predictors of risk

Fig. 1. Receiver operating characteristic (ROC) curves for fasting insulin concentration (μIU/mL) (*A*), homeostatic model assessment-insulin resistance (HOMA-IR; ([mg × μIU] ÷ [dL × mL]) (*B*), and 2-hour glucose (mg/dL) (*C*), derived from an oral glucose tolerance test performed 24 hours after 8 mg of Dex. ROC curves are shown for the three parameters, and the area under the curve (AUC) for each curve is shown in each panel. Sensitivities and specificities at different cut-points are shown below each panel.

for development of T2DM over a 7-year period. The present study extends these observations by supplying ROC curves with sensitivity and specificity values.

The present study has some limitations. First, this was a relatively small pilot study performed as proof of concept. Hence, the "Dex Stress Test" requires validation in large population-based studies in different ethnic groups. Second, we used an 8-mg dose of Dex, and it is possible that a somewhat higher dose (e.g., 12 mg) would have resulted in higher discrimination. Third, the study had enrolled significantly more females than males, which may have skewed the results. Finally, the observed rate of conversion to T2DM in this study (with 9 of 33 individuals over 7 years) is lower than some previous reports (30-32); the reasons for this finding are not known but might reflect differences in ethnic background.

CONCLUSION

We conclude that the Dex Stress Test appears to be a good to excellent predictive test for identifying persons that are highly prone to develop T2DM. Once validated in a large population-based study, the test would have great utility in focusing our resources and efforts for prevention of diabetes on those individuals that are highly prone to develop the disease.

ACKNOWLEDGMENT

We thank Ms. Kelley Carr for assistance with the tables and Figure 1. The study was funded by the Isfahan Endocrine and Metabolism Research Center at Isfahan University of Medical Sciences. Dr. Taheri performed the study under supervision of Drs. Amini and Aminorroaya. Dr. Ismail-Beigi reviewed the data and wrote the first draft. All authors have had input into the manuscript and agree with the submitted version. Study registry number: IRCT201111308258N1.

DISCLOSURE

Drs. Taheri, Aminorroaya, and Amini have no multiplicity of interest to disclose. Dr. Ismail-Beigi has received research grants from the National Institutes of Health and Novo-Nordisk, is a consultant to Sanofi, Bayer, and Covance, and has shares in Thermalin Diabetes; there is no conflict with this study.

REFERENCES

1. **Hu FB, Satija A, Manson JE.** Curbing the diabetes pandemic: the need for global policy solutions. *JAMA*. 2015;313:2319-2320.
2. **Weng J-P, Hu G.** Diabetes: leveraging the tipping point of the diabetes pandemic. *Diabetes*. 2017;66:1461-1463.
3. **Ye Q, Fu JF.** Paediatric type 2 diabetes in China—pandemic, progression, and potential solutions. *Pediatric Diabetes*. 2018;19:27-35.
4. **Caspard H, Jabbour S, Hammar N, Fenici P, Sheehan JJ, Kosiborod M.** Recent trends in the prevalence of type 2 diabetes and the association with abdominal obesity lead to growing health disparities in the USA: an analysis of the NHANES surveys from 1999 to 2014. *Diabetes Obes Metab*. 2018;20:667-671.
5. **Kivimäki M, Kuosma E, Ferrie JE, et al.** Overweight, obesity, and risk of cardiometabolic multimorbidity: pooled analysis of individual-level data for 120 813 adults from 16 cohort studies from the USA and Europe. *Lancet Public Health*. 2017;2:e277-e285.

6. **Abdul-Ghani MA, Williams K, DeFronzo RA, Stern M.** What is the best predictor of future type 2 diabetes? *Diabetes Care*. 2007;30:1544-1548.

7. **Nanri A, Nakagawa T, Kuwahara K, et al.** Development of risk score for predicting 3-year incidence of type 2 diabetes: Japan Epidemiology Collaboration on Occupational Health Study. *PloS One*. 2015;10:e0142779.

8. **Zhang H, Wang C, Ren Y, et al.** A risk-score model for predicting risk of type 2 diabetes mellitus in a rural Chinese adult population: a cohort study with a 6-year follow-up. *Diabetes Metab Res Rev*. 2017;33.

9. **Pagano G, Cavallo-Perin P, Cassader M, et al.** An in vivo and in vitro study of the mechanism of prednisone-induced insulin resistance in healthy subjects. *J Clin Invest*. 1983;72:1814-1820.

10. **Perley M, Kipnis DM.** Effect of glucocorticoids on plasma insulin. *N Engl J Med*. 1966;274:1237-1241.

11. **Yuen KC, McDaniel PA, Riddle MC.** Twenty-four-hour profiles of plasma glucose, insulin, C-peptide and free fatty acid in subjects with varying degrees of glucose tolerance following short-term, medium-dose prednisone (20 mg/day) treatment: evidence for differing effects on insulin secretion and action. *Clin Endocrinol*. 2012;77:224-232.

12. **Beard J, Halter J, Best J, Pfeifer M, Porte D Jr.** Dexamethasone-induced insulin resistance enhances B cell responsiveness to glucose level in normal men. *Am J Physiol*. 1984;247(5 Pt 1):E592-E596.

13. **Conn J, Fajans S.** Influence of adrenal cortical steroids on carbohydrate metabolism in man. *Metabolism*. 1956;5:114-127.

14. **Fajans SS, Conn JW.** An approach to the prediction of diabetes mellitus by modification of the glucose tolerance test with cortisone. *Diabetes*. 1954;3:296-304.

15. **Kauh E, Mixson L, Shankar S, et al.** Short-term metabolic effects of prednisone administration in healthy subjects. *Diabetes Obes Metab*. 2011;13:1001-1007.

16. **Larsson H, Ahrén B.** Insulin resistant subjects lack islet adaptation to short-term dexamethasone-induced reduction in insulin sensitivity. *Diabetologia*. 1999;42:936-943.

17. **Nicod N, Giusti V, Besse C, Tappy L.** Metabolic adaptations to dexamethasone-induced insulin resistance in healthy volunteers. *Obes Res*. 2003;11:625-631.

18. **Rull JA, Conn J, Floyd JC Jr, Fajans SS.** Levels of plasma insulin during cortisone glucose tolerance tests in "nondiabetic" relatives of diabetic patients: implications of diminished insulin secretory reserve in subclinical diabetes. *Diabetes*. 1970;19:1-10.

19. **Wajngot A, Giacca A, Grill V, Vranic M, Efendic S.** The diabetogenic effects of glucocorticoids are more pronounced in low-than in high-insulin responders. *Proc Natl Acad Sci U S A*. 1992;89: 6035-6039.

20. **Taheri N, Aminorroaya A, Ismail-Beigi F, Amini M.** Effect of dexamethasone on glucose homeostasis in normal and prediabetic subjects with a first-degree relative with type 2 diabetes mellitus. *Endocr Pract*. 2012;18:855-863.

21. **Abdelmannan D, Tahboub R, Genuth S, Ismail-Beigi F.** Effect of dexamethasone on oral glucose tolerance in healthy adults. *Endocr Pract*. 2010;16:770-777.

22. **Marathe PH, Gao HX, Close KL.** American Diabetes Association standards of medical care in diabetes 2017. *J Diabetes*. 2017;9: 320-324.

23. **Metz CE.** Basic principles of ROC analysis. *Seminars in Nuclear Medicine*. Elsevier; 1978: 283-298.

24. **Stern MP, Williams K, Haffner SM.** Identification of persons at high risk for type 2 diabetes mellitus: do we need the oral glucose tolerance test? *Ann Intern Med*. 2002;136:575-581.

25. **Durck TT, Henriksen JE, Egede MB, et al.** The metabolic responses induced by acute dexamethasone predict glucose tolerance and insulin secretion over 10 years in relatives of type 2 diabetic subjects. *Diabetes Metab Res Rev*. 2013;29:492-498.

26. **Walker M, Mari A, Jayapaul M, Bennett S, Ferrannini E.** Impaired beta cell glucose sensitivity and whole-body insulin sensitivity as predictors of hyperglycaemia in non-diabetic subjects. *Diabetologia*. 2005;48:2470-2476.

27. **Alvarsson M, Wajngot A, Cerasi E, Efendic S.** K-value and low insulin secretion in a non-obese white population: predicted glucose tolerance after 25 years. *Diabetologia*. 2005;48: 2262-2268.

28. **Hanley A, Wagenknecht L, Norris JM, et al.** Insulin resistance, beta cell dysfunction and visceral adiposity as predictors of incident diabetes: the Insulin Resistance Atherosclerosis Study (IRAS) family study. *Diabetologia*. 2009;52:2079-2086.

29. **Ferrannini E, Massari M, Nannipieri M, Natali A, Ridaura RL, Gonzales-Villalpando C.** Plasma glucose levels as predictors of diabetes: the Mexico City diabetes study. *Diabetologia*. 2009;52:818-824.

30. **Tataranni PA, Bogardus C.** Changing habits to delay diabetes. *N Engl J Med*. 2001;344:1390-1392.

31. **Tuomilehto J, Lindström J, Eriksson JG, et al.** Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. *N Engl J Med*. 2001;344: 1343-1350.

32. **Knowler WC, Barrett-Connor E, Fowler SE, et al.** Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. *N Engl J Med*. 2002;346:393-403.